In vivo demonstration of M3 muscarinic receptor subtype selectivity of Darifenacin (cas 133099-04-4) in mice

Add time:09/08/2019    Source:sciencedirect.com

A novel muscarinic receptor antagonist, Darifenacin (cas 133099-04-4), inhibited specific binding of [N-methyl-3H]scopolamine ([3H]NMS) in the mouse bladder, submaxillary gland and heart in a concentration-dependent manner. The inhibitory effect was most potent in the submaxillary gland, followed by the bladder and heart. In addition, darifenacin inhibited specific [3H]NMS binding in the membranes of CHO-K1 cell lines expressing muscarinic M2 and M3 receptor subtypes, and the potency was significantly (22-fold) greater at the M3 than at the M2 subtype. At 0.5 to 12 h after oral administration of darifenacin, a significant increase in Kd values for specific [3H]NMS binding was seen in the bladder, submaxillary gland and lung of mice, compared with control values. Also, there was a sustained decrease in the Bmax values in the submaxillary gland. These data suggest that muscarinic receptor binding of oral darifenacin is rapid in onset and of a long duration. On the other hand, oral darifenacin exerted only temporary or little binding of muscarinic receptors in the heart and colon. Pilocarpine-induced salivary secretion in mice was continuously suppressed by oral darifenacin. The time-course of suppression coincided well with that for the muscarinic receptor binding in the submaxillary gland. The antagonistic effect of darifenacin against the dose–response curves for pilocarpine appeared to be insurmountable. In conclusion, the present study has shown that oral darifenacin may exert a pronounced and long-lasting binding of muscarinic receptors in tissues expressing the M3 subtype.

We also recommend Trading Suppliers and Manufacturers of Darifenacin (cas 133099-04-4). Pls Click Website Link as below: cas 133099-04-4 suppliers

Prev:Neuro-urologyDifferential Effects of the Antimuscarinic Agents Darifenacin (cas 133099-04-4) and Oxybutynin ER on Memory in Older Subjects
Next:Female Urology—IncontinenceTreatment of Overactive Bladder in the Older Patient: Pooled Analysis of Three Phase III Studies of Darifenacin (cas 133099-04-4), an M3 Selective Receptor Antagonist)